ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Translational Session

Translating Kidney Research Pathways into Novel Drugs: Lesson Learned as We Usher in the Future

October 25, 2020 | 10:00 AM - 12:00 PM

Location: On-Demand

Session Description

The need for novel drugs that target renal cells is larger than ever, with an increasing number of people developing kidney diseases. The drug regulatory pathway has been modified to facilitate the development of novel agents. The translation of discovered pathways into concepts and ultimately drug development has the potential to affect kidney health in a large number of patients. This session reviews what has been learned from these developments, which are supported by KidneyX, a public-private partnership to spark innovation.

Learning Objective(s)

  • Outline the regulatory and drug development pathway for novel drugs
  • Identify the different drugs that can affect people with kidney diseases
  • Discuss new tools, databases, big data, and initiatives that help spark innovation and develop new agents
  • Describe animal and in silico models for kidney disease
  • Explain the role of stem cells and organoids in drug discovery and regenerative renal medicine

Learning Pathway(s)

  • Glomerular Diseases
  • Chronic Kidney Disease

Moderators

  • Jenny C. Nystrom, PhD
  • Martin R. Pollak, MD

Presentations

  • Regulatory Pathways and Drug Development Milestones: Lessons Learned
    10:00 AM - 10:30 AM
    Aliza M. Thompson, MD, MS
  • Drug Screens, Assay Systems, and Big Data Integration Aiding Kidney Drug Development
    10:30 AM - 11:00 AM
    Vineet Gupta, PhD
  • Which Drug for Which Disease? Small Molecules to Antibodies to Devices
    11:00 AM - 11:30 AM
    Matthew Douglas Breyer, MD, FASN 
  • KidneyX: A New Path for Innovation, Diagnosis, and Treatment of Kidney Diseases
    11:30 AM - 12:00 PM
    John R. Sedor, MD, FASN